Satoshi Yoda

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in <i>ALK</i> -Rearranged Lung Cancer

Justin F. Gainor, Leila Dardaei, Satoshi Yoda et al. · Cancer Discovery · 2016 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +10

Landscape of Acquired Resistance to Osimertinib in <i>EGFR</i> -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired <i>RET</i> Fusion

Zofia Piotrowska, Hideko Isozaki, Jochen K. Lennerz et al. · Cancer Discovery · 2018 · 445 citations

Medicine, Oncology, Pharmacology +17

Impact of <i>EML4-ALK</i> Variant on Resistance Mechanisms and Clinical Outcomes in <i>ALK</i>-Positive Lung Cancer

Viola W. Zhu, Satoshi Yoda, Beow Y. Yeap et al. · Journal of Clinical Oncology · 2018 · 337 citations · Full text

Medicine, Oncology, Pharmacology +17

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound <i>ALK</i> Mutations in ALK-Positive Lung Cancer

Satoshi Yoda, Michael S. Lawrence, Benjamin J. Burke et al. · Cancer Discovery · 2018 · 306 citations · Full text

Medicine, Molecular Medicine, Oncology +16

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies

Benjamin Solomon, Lavinia Tan, Stephen Q. Wong et al. · Journal of Thoracic Oncology · 2020 · 284 citations · Full text

Medicine, Oncology, Pharmacology +17